{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=24", "query": { "intervention": "nivolumab", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 1207, "total_pages": 121, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T18:55:57.864Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02335918", "title": "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Ovarian Carcinoma-Enrollment Completed", "Colorectal Cancer (CRC)-Enrollment Completed", "Renal Cell Carcinoma (RCC) (Phase ll Only)", "Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed" ], "interventions": [ { "name": "Combination of varlilumab and nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2015-01", "completion_date": "2018-12-12", "has_results": false, "last_update_posted_date": "2019-12-09", "last_synced_at": "2026-10-24T18:55:57.864Z", "location_count": 19, "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02335918" }, { "nct_id": "NCT03554317", "title": "COMbination of Bipolar Androgen Therapy and Nivolumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-resistant Prostate Cancer", "Metastatic Prostate Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Testosterone cypionate", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 45, "start_date": "2018-09-05", "completion_date": "2023-01-06", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-10-24T18:55:57.864Z", "location_count": 3, "location_summary": "San Francisco, California • Baltimore, Maryland • Boston, Massachusetts", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03554317" }, { "nct_id": "NCT02073123", "title": "Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Stage III Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "Indoximod", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2014-07", "completion_date": "2019-07-03", "has_results": true, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-24T18:55:57.864Z", "location_count": 6, "location_summary": "Augusta, Georgia • Iowa City, Iowa • Rochester, Minnesota + 3 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02073123" }, { "nct_id": "NCT03370276", "title": "Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Oropharynx", "Squamous Cell Carcinoma of the Larynx", "Squamous Cell Carcinoma of the Oral Cavity", "Squamous Cell Carcinoma of the Hypopharynx", "Squamous Cell Carcinoma of the Paranasal Sinus", "Head and Neck Squamous Cell Carcinoma", "Squamous Cell Cancer", "Head and Neck Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2017-12-20", "completion_date": "2023-12-23", "has_results": true, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-24T18:55:57.864Z", "location_count": 3, "location_summary": "Tampa, Florida • Atlanta, Georgia • Columbus, Ohio", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03370276" }, { "nct_id": "NCT06624475", "title": "Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Basal Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Relatlimab plus Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-08-21", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-24T18:55:57.864Z", "location_count": 3, "location_summary": "Irvine, California • La Jolla, California • San Francisco, California", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06624475" }, { "nct_id": "NCT04019964", "title": "Nivolumab in Biochemically Recurrent dMMR Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Recurrent Prostate Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 8, "start_date": "2020-01-13", "completion_date": "2025-07-03", "has_results": true, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-24T18:55:57.864Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04019964" }, { "nct_id": "NCT03036098", "title": "Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1314, "start_date": "2017-03-24", "completion_date": "2026-05-15", "has_results": true, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-10-24T18:55:57.864Z", "location_count": 29, "location_summary": "Anchorage, Alaska • Fresno, California • Santa Rosa, California + 24 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Fresno", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03036098" }, { "nct_id": "NCT03465592", "title": "Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sarcoma", "Solid Tumor, Adult", "Solid Tumor, Childhood" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "40 Years", "sex": "ALL", "summary": "12 Months to 40 Years" }, "enrollment_count": 39, "start_date": "2018-05-01", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-24T18:55:57.864Z", "location_count": 4, "location_summary": "St. Petersburg, Florida • Baltimore, Maryland • The Bronx, New York + 1 more", "locations": [ { "city": "St. Petersburg", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "The Bronx", "state": "New York" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03465592" }, { "nct_id": "NCT05987332", "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "IDE196", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDEAYA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2023-10-31", "completion_date": "2028-01-15", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-10-24T18:55:57.864Z", "location_count": 31, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05987332" }, { "nct_id": "NCT04143711", "title": "Study of DF1001 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "DF1001", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2019-11-11", "completion_date": "2025-12-05", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-24T18:55:57.864Z", "location_count": 16, "location_summary": "Irvine, California • Los Angeles, California • San Diego, California + 13 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04143711" } ] }